Clinical trials: Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to compare the efficacy and safety of a new basal insulin, insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02106364
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- 10 sites in United States
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-
This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.
- Trial name
- NCT00297063
- Testing
- Rosiglitazone
- Where
- 14 sites in Japan
- Volunteers
- 350 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
This clinical study aims to evaluate the effects of using the "WellCheck" mobile application on blood glucose, blood pressure, and weight among Type 2 diabetes patients in real primary care settings.
- Trial name
- NCT06419816
- Testing
- Physician-managed "WellCheck" use, self-managed "WellCheck" use
- Where
- South Korea
- Volunteers
- 471 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
A Study of LY2599506 in Patients With Type 2 Diabetes
The purpose of this study is to help answer the following questions: To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks.
- Trial name
- NCT01024244
- Testing
- LY2599506
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 78 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Renal Insufficiency
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have reduced kidney function.
- Trial name
- NCT01064414
- Testing
- Canagliflozin
- Where
- 106 sites in United States, Australia and 16 more
- Volunteers
- 272 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients
The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study safety and tolerability in patients with type 2 diabetes.
- Trial name
- NCT00690287
- Testing
- AZD6370
- Where
- 3 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2…
- Trial name
- NCT06688123
- Testing
- SHR-3167, Insulin glargine
- Where
- 2 sites in China
- Volunteers
- 275 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.
- Trial name
- NCT01196546
- Testing
- vildagliptin/metformin
- Where
- 8 sites in Thailand
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novartis
Type 2 Diabetes
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of single and multiple doses of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector…
- Trial name
- NCT04001231
- Testing
- Exenatide Once-Weekly Suspension
- Sponsor
- AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
The purpose of this study is to evaluate the effect of ISIS 449884 (ISIS-GCGRRX) on Hepatic Lipid and Glycogen Content in patients with Type 2 Diabetes being treated with Metformin.
- Trial name
- NCT02824003
- Testing
- ISIS-GCGRRx
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in…
- Trial name
- NCT00325429
- Testing
- Vildagliptin
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall…
- Trial name
- NCT00099931
- Testing
- vildagliptin
- Where
- Germany
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension…
- Trial name
- GETGOAL-MONO (NCT00905255)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2, Hyperglycaemia (Diabetic)
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance.
- Conditions
- Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in, Torsades de Pointes
- Trial name
- NCT07014735
- Testing
- glucose, moxifloxacin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Richmond Pharmacology Limited
Type 2 Diabetes
Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)
To compare in terms of HbA1c insulin naive patients with Type 2 Diabetes starting with insulin glargine on an algorithm with insulin naive patients starting with insulin glargine on the physician's standard practice.
- Trial name
- Malbec (NCT00627471)
- Testing
- Insulin Glargine
- Where
- Argentina
- Volunteers
- 9 people
- Sponsor
- Sanofi
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Primary Objective: To compare the effect of sotagliflozin to placebo on the total occurrences of cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (HF) in hemodynamically…
- Trial name
- NCT03521934
- Testing
- Sotagliflozin
- Where
- 466 sites in United States, Argentina and 30 more
- Volunteers
- 1,222 people
- Sponsor
- Lexicon Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.